CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 98 enrolled
Drug / intervention
Sitravatinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04734262
NCT04734262Phase 2Unknown
CompareCT.gov

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Fudan University·interventional·Posted Feb 2, 2021·Updated Nov 18, 2023

In Brief

A Phase 2 clinical trial evaluating Sitravatinib, Tislelizumab, and 1 other intervention for Metastatic Breast Cancer. Targeting 98 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the efficacy and safety of sitravatinib plus tislelizumab or combination with nab-paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC) patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
202120222023202420252026
First PostedFeb 2, 2021
Enrollment StartApr 1, 2021
Primary CompletionJun 30, 2024
TodayJul 1, 2026
Enrollment to primary: 3.2 yearsPosted 5.4 years ago

Interventions

Sitravatinibdrug

Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Tislelizumabdrug

Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody

Nab-paclitaxeldrug

Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin